• About us
• Contact

Advertisement

Organisation › Details

CureVac GmbH

CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is advancing the field of mRNA-based vaccination. The company uses its technology platforms for the development of novel therapeutic mRNA vaccines (RNActive®) for cancer and prophylactic vaccines for infectious diseases. Furthermore CureVac develops adjuvants based on non-coding RNAs (RNAdjuvant®) for enhancing the immune response of other vaccines. The company has successfully completed Phase I/IIa studies with its RNActive® cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). Results so far have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses. CureVac is currently running a number of clinical trials with its RNActive® vaccines, including a large randomized Phase IIb clinical trial in prostate cancer. In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur,In-Cell-Art and Janssen Pharmaceuticals for the development of prophylactic vaccines in infectious diseases utilizing its RNActive® technology platform. *

 

	Start	2000-08-01 established
	End	2015-11-03 renamed
	Group	CureVac (Group)
	Today	CureVac AG
	Predecessor	University of Tübingen (Eberhard-Karls-Universität)
	Successor	CureVac AG
	Industry	RNAi technology
	Industry 2	RNActive® vaccination technology
	Region	Tübingen
	Country	Germany
	Street	15 Friedrich-Miescher-Str.
	City	72076 Tübingen
	Tel	+49-7071-92053-0
		Address record changed: 2020-12-11
Basic data	Employees	C: 51 to 100 (2011-05-27)
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for CureVac (Group)

• [1] CureVac N.V.. (4/7/25). "Press Release: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer". Tübingen & Boston, MA....
• [2] Agomab Therapeutics N.V.. (7/11/24). "Press Release: Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer". Antwerp....
• [3] CureVac N.V.. (7/3/24). "Press Release: CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities". Tübingen & Boston, MA....
• [4] CureVac N.V.. (7/3/24). "Press Release: GSK and CureVac to Restructure Collaboration into New Licensing Agreement". London, Tübingen & Boston, MA....
• [5] CureVac N.V.. (5/28/24). "Press Release: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK". Tübingen & Boston, MA....
• [6] CureVac N.V.. (4/24/24). "Press Release: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer". Tübingen & Boston, MA....
• [7] CureVac N.V.. (4/16/24). "Press Release: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines". Tübingen & Houston, TX....
• [8] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
• [9] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
• [10] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.